{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:02Z","timestamp":1791595322812,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Fund of Clinical and Translational Research Project of Anhui Province","award":["202427b10020044"],"award-info":[{"award-number":["202427b10020044"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370225"],"award-info":[{"award-number":["82370225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06797-5","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:18:02Z","timestamp":1770175082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated circulating CD10\u2212granulocytic myeloid-derived suppressor cells correlate with disease activity and poor prognosis in patients with diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Yingwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunyi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"6797_CR1","doi-asserted-by":"publisher","unstructured":"Crump M, Neelapu SS, Farooq U et al(2018)Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 131(5):587\u2013588. https:\/\/doi.org\/10.1182\/blood-2017-11-817775","DOI":"10.1182\/blood-2017-11-817775"},{"key":"6797_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"6797_CR3","doi-asserted-by":"publisher","unstructured":"Wang Y, Shi Q, Shi ZY et al(2024)Biological signatures of the international prognostic index in diffuse large B-cell lymphoma. Blood 8(7):1587\u20131599. https:\/\/doi.org\/10.1182\/bloodadvances","DOI":"10.1182\/bloodadvances"},{"issue":"3","key":"6797_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41375-023-02120-7","volume":"38","author":"W Ren","year":"2024","unstructured":"Ren W, Wan H, Own SA et al (2024) Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis. Leukemia 38(3):610\u2013620. https:\/\/doi.org\/10.1038\/s41375-023-02120-7","journal-title":"Leukemia"},{"issue":"6","key":"6797_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s12026-024-09537-x","volume":"72","author":"J Vaughan","year":"2024","unstructured":"Vaughan J, Wiggill T, Mia Z et al (2024) Tumour-associated macrophages in diffuse large B-cell lymphoma: the prognostic and therapeutic impact in a South African centre with high HIV seroprevalence. Immunol Res 72(6):1393\u20131403. https:\/\/doi.org\/10.1007\/s12026-024-09537-x","journal-title":"Immunol Res"},{"key":"6797_CR6","doi-asserted-by":"publisher","unstructured":"Autio M, Br\u00fcck O, Pollari M et al (2024)Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas. Haematologica. https:\/\/doi.org\/10.3324\/haematol","DOI":"10.3324\/haematol"},{"issue":"1","key":"6797_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.","volume":"380","author":"P Qu","year":"2016","unstructured":"Qu P, Wang LZ, Lin PC (2016) Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Lett 380(1):253\u20136. https:\/\/doi.org\/10.1016\/j.canlet.","journal-title":"Cancer Lett"},{"issue":"4","key":"6797_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253\u201368. https:\/\/doi.org\/10.1038\/nri3175","journal-title":"Nat Rev Immunol"},{"key":"6797_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin N (2020) The development and homing of myeloid-derived suppressor cells: from a two-stage model to a multistep narrative. Front Immunol 11:557586. https:\/\/doi.org\/10.3389\/fimmu.","journal-title":"Front Immunol"},{"key":"6797_CR10","doi-asserted-by":"crossref","unstructured":"Lang S, Bruderek K, Kaspar C et al (2018) Clinical relevance and suppressive capacity of human Myeloid-Derived suppressor cell subsets. Clin Cancer Res 24(19):4834\u20134844. doi: 10. 1158\/1078\u2009\u2013\u20090432.","DOI":"10.1158\/1078-0432.CCR-17-3726"},{"issue":"1","key":"6797_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu X, Weber R et al (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer 120(1):16\u201325. https:\/\/doi.org\/10.1038\/s41416-018-0333-1","journal-title":"Br J Cancer"},{"key":"6797_CR12","doi-asserted-by":"publisher","unstructured":"Sun R, Xiong Y, Liu H et al(2020) Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1\/PD-1 axis. Transl Oncol 13(10):100825. https:\/\/doi.org\/10.1016\/j.tranon","DOI":"10.1016\/j.tranon"},{"issue":"19","key":"6797_CR13","doi-asserted-by":"publisher","first-page":"27676","DOI":"10.18632\/oncotarget.8507","volume":"7","author":"O Marini","year":"2016","unstructured":"Marini O, Spina C, Mimiola E et al (2016) Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget 7(19):27676\u201388. https:\/\/doi.org\/10.18632\/oncotarget.8507","journal-title":"Oncotarget"},{"issue":"5","key":"6797_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.616","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang J, Zhu F et al (2022) Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin\u2019s lymphoma patients. Immun Inflamm Dis 10(5):e616. https:\/\/doi.org\/10.1002\/iid3.616","journal-title":"Immun Inflamm Dis"},{"issue":"3","key":"6797_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.19746\/j.cnki.issn","volume":"27","author":"CX Wu","year":"2019","unstructured":"Wu CX, Qiang M, Hao JQ (2019) Prognostic value of CD14+HLA-DRlow\/\u2212 myeloid derived suppressor cells in diffuse large B cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27(3):816\u2013819. https:\/\/doi.org\/10.19746\/j.cnki.issn","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"8","key":"6797_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081768","volume":"10","author":"Z Wang","year":"2021","unstructured":"Wang Z, Jiang R, Li Q et al (2021) Elevated M-MDSCs in circulation are indicative of poor prognosis in diffuse large B-cell lymphoma patients. J Clin Med 10(8):1768. https:\/\/doi.org\/10.3390\/jcm10081768","journal-title":"J Clin Med"},{"issue":"1","key":"6797_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/1878-0261.12834.","volume":"15","author":"R Sun","year":"2021","unstructured":"Sun R, Zheng Z, Wang L et al (2021) A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression. Mol Oncol 15(1):246\u2013261. https:\/\/doi.org\/10.1002\/1878-0261.12834.","journal-title":"Mol Oncol"},{"issue":"6","key":"6797_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002323","volume":"9","author":"C Jim\u00e9nez-Cortegana","year":"2021","unstructured":"Jim\u00e9nez-Cortegana C, Palaz\u00f3n-Carri\u00f3n N, Martin Garcia-Sancho A et al (2021) Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory\/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J Immunother Cancer 9(6):e002323. https:\/\/doi.org\/10.1136\/jitc-2020-002323","journal-title":"J Immunother Cancer"},{"issue":"6","key":"6797_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/jleuko\/qiae032","volume":"115","author":"LF Pu","year":"2024","unstructured":"Pu LF, Li MM, Feng XJ et al (2024) Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin\u2019s lymphoma. J Leukoc Biol 115(6):1094\u20131107. https:\/\/doi.org\/10.1093\/jleuko\/qiae032","journal-title":"J Leukoc Biol"},{"issue":"2","key":"6797_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaf8943.","volume":"1","author":"T Condamine","year":"2016","unstructured":"Condamine T, Dominguez GA, Youn JI et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 1(2):aaf8943. https:\/\/doi.org\/10.1126\/sciimmunol.aaf8943.","journal-title":"Sci Immunol"},{"issue":"10","key":"6797_CR21","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2016-04-713206","volume":"129","author":"O Marini","year":"2017","unstructured":"Marini O, Costa S, Bevilacqua D et al (2017) Mature CD10+ and immature CD10\u2212 neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood 129(10):1343\u20131356. https:\/\/doi.org\/10.1182\/blood-2016-04-713206","journal-title":"Blood"},{"issue":"4","key":"6797_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/imcb.12728.","volume":"102","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xiao H, Wang Z et al (2024) CD14-CD10-CD45\u2009+\u2009HLA-DR-SSC\u2009+\u2009neutrophils may be granulocytic myeloid-derived suppressor cell-like cells and relate to disease progression in non-Hodgkin\u2019s lymphoma patients. Immunol Cell Biol 102(4):256\u2013268. https:\/\/doi.org\/10.1111\/imcb.12728.","journal-title":"Immunol Cell Biol"},{"key":"6797_CR23","doi-asserted-by":"publisher","DOI":"10.25259\/Cytojournal_165_2024","volume":"21","author":"M Xiao","year":"2024","unstructured":"Xiao M, Zhou J, Zhang W et al (2024) Association of immunosuppressive CD45+CD33+CD14\u2212 CD10\u2212HLA-DR\u2212\/low neutrophils with poor prognosis in patients with lymphoma and their expansion and activation through STAT3\/arginase-1 pathway <Emphasis Type=\"Italic\">in vitro<\/Emphasis>. Cytojournal 21:69. https:\/\/doi.org\/10.25259\/Cytojournal_165_2024","journal-title":"Cytojournal"},{"issue":"14","key":"6797_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7448","volume":"13","author":"I Dogliotti","year":"2024","unstructured":"Dogliotti I, Peri V, Clerico M et al (2024) Real life clinical outcomes of relapsed\/refractory diffuse large B cell lymphoma in the rituximab era: the STRIDER study. Cancer Med 13(14):e7448. https:\/\/doi.org\/10.1002\/cam4.7448","journal-title":"Cancer Med"},{"issue":"6","key":"6797_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6991","volume":"13","author":"X Dang","year":"2024","unstructured":"Dang X, Li P, Shen A et al (2024) Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy. Cancer Med 13(6):e6991. https:\/\/doi.org\/10.1002\/cam4.6991","journal-title":"Cancer Med"},{"key":"6797_CR26","doi-asserted-by":"publisher","unstructured":"Miljkovic M, Dragos VS, Gasljevic G et al (2025) Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic Index? Radiol Oncol. https:\/\/doi.org\/10.2478\/raon-2025-0028","DOI":"10.2478\/raon-2025-0028"},{"issue":"2","key":"6797_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70047","volume":"43","author":"Y Nato","year":"2025","unstructured":"Nato Y, Miyazaki K, Maruyama D et al (2025) Treatments and outcomes of newly diagnosed CD5-positive diffuse large B-cell lymphoma: a multi-institutional observational study. Hematol Oncol 43(2):e70047. https:\/\/doi.org\/10.1002\/hon.70047","journal-title":"Hematol Oncol"},{"key":"6797_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303959","volume":"14","author":"S Dhar","year":"2024","unstructured":"Dhar S, Chakravarti M, Ganguly N et al (2024) High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP. Front Immunol 14:1303959. https:\/\/doi.org\/10.3389\/fimmu.2023.1303959","journal-title":"Front Immunol"},{"key":"6797_CR29","doi-asserted-by":"publisher","first-page":"104254","DOI":"10.1016\/j.cellimm","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S et al (2021) )IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 359:104254. https:\/\/doi.org\/10.1016\/j.cellimm","journal-title":"Cell Immunol"},{"issue":"2","key":"6797_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S et al (2021) The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers (Basel) 13(2):210. https:\/\/doi.org\/10.3390\/cancers13020210","journal-title":"Cancers (Basel)"},{"key":"6797_CR31","doi-asserted-by":"publisher","unstructured":"Peng X, Shi J, Sun W et al (2018) Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget 9(15):12351\u201312364. https:\/\/doi.org\/10.18632\/oncotarget","DOI":"10.18632\/oncotarget"},{"issue":"5","key":"6797_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14370","volume":"27","author":"S Xie","year":"2024","unstructured":"Xie S, Zhu L, Wang L et al (2024) Assessment and prognostic significance of a serum cytokine panel in diffuse large B-cell lymphoma. Oncol Lett 27(5):237. https:\/\/doi.org\/10.3892\/ol.2024.14370","journal-title":"Oncol Lett"},{"key":"6797_CR33","doi-asserted-by":"publisher","unstructured":"Zhong W, Xu X, Zhu Z et al (2018) Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol 52(5):1528\u20131538. https:\/\/doi.org\/10.3892\/ijo.2018.4299","DOI":"10.3892\/ijo.2018.4299"},{"issue":"1","key":"6797_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1081-7.","volume":"38","author":"W Zhong","year":"2019","unstructured":"Zhong W, Zhu Z, Xu X et al (2019) Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. J Exp Clin Cancer Res 38(1):73. https:\/\/doi.org\/10.1186\/s13046-019-1081-7.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06797-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06797-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:05:38Z","timestamp":1771949138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06797-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6797"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06797-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}